Ecotropic viral integration site 1 (EVI1) is an oncogenic transcription factor in human acute myeloid leukemia (AML) with chromosomal alterations at 3q26. Because a high expression of EVI1 protein in AML cells predicts resistance to chemotherapy with a poor outcome, we have searched for molecular targets that will treat these patients with AML. In this study, we determined that CD52, which is mainly expressed on lymphocytes, is highly expressed in most cases of AML with a high EVI1 expression (EVI1 High ). CAMPATH-1H, a humanized monoclonal antibody against CD52, has been used to prevent graft-versus-host disease and treat CD52-positive lymphoproliferative disorders. Here, we investigated the antitumor effect of CAMPATH-1H on EVI1
Introduction
Murine ecotropic viral integration site 1 (EVI1) was first identified as a leukemia-associated gene activated by murine retroviral integration. 1, 2 A high expression of the human homologue EVI1 is found in 5-10% of patients with acute myeloid leukemia (AML), but chromosome 3q26 abnormalities near the EVI1 gene are only detected in 1-3% of all AML cases. [3] [4] [5] Because AML patients with a high EVI1 expression (EVI1 High ) had a significantly reduced overall survival, overexpression of the EVI1 gene is thought to be a poor prognostic factor for AML patients. 6, 7 Patients with EVI1 High AML often do not respond to chemotherapy and hematopoietic cell transplantation; 8 
therefore, identifying novel molecular targets in EVI1
High AML is of particular importance. In this study, we identified CD52 as a new surface molecule highly expressed on most EVI1
High leukemia cells by DNA microarray, reverse-transcription polymerase chain reaction (RT-PCR) and flow cytometry analyses.
Human CD52 is a glycosylphosphatidylinositol-anchored antigen expressed on the cell surfaces of normal and malignant lymphocytes. [9] [10] [11] Although the function of CD52 is largely unknown, CD52 is a favored target for lymphoma therapy and immunosuppression before bone marrow transplantation. [12] [13] [14] [15] Alemtuzumab (CAMPATH-1H; Genzyme, Cambridge, MA, USA) is a recombinant humanized monoclonal antibody targeting the CD52 antigen. 16, 17 The binding of CAMPATH-1H to CD52 on lymphocytes induces complement-dependent cytotoxicity (CDC), 18, 19 antibody-dependent cell-mediated cytotoxicity (ADCC) [20] [21] [22] and direct cytotoxicity. 23, 24 Here, we examined the cytotoxic effects of CAMPATH-1H on EVI1 High leukemia cells in vitro and the effects of CAMPATH-1H treatment on tumor growth in immunodeficient NOD/Shi-scid/ IL-2Rgnull (NOG) mice xenografted with EVI1
High leukemia cells. Because CAMPATH-1H showed a direct cytotoxic effect, CDC and ADCC activity, as well as an in vivo antitumor effect against EVI1
High AML cells, CAMPATH-1H is likely to be a good therapeutic agent for AML with EVI1
High expression.
Materials and methods

Cell lines
UCSD/AML1 (refs 25, 26) cells derived from human AML were cultured in RPMI 1640 medium (Wako, Osaka, Japan) supplemented with 10% fetal bovine serum and 1 ng/ml granulocytemacrophage colony-stimulating factor. 
Patient samples
Leukemia cells were obtained from the peripheral blood (PB) of AML patients who had a blast population of more than 80% in their PB at diagnosis before chemotherapy (Supplementary  Table 2 ). After Ficoll-Hypaque (Sigma, Saint Louis, MO, USA) separation of the PB, the purity of the blast cells was confirmed by flow cytometry using immunofluorescence staining of phycoerythrin-conjugated CD11b and CD33 (Supplementary Figure S2) . The study was approved by the Institutional Review Board of the Faculty of Medicine, University of Miyazaki. Informed consent was obtained from all blood and tissue donors according to the Declaration of Helsinki.
Antibodies
The human monoclonal antibody CAMPATH-1H that recognizes CD52 was obtained from Bayer Schering Pharma AG (Berlin-Wedding, Germany). The antibody against caspase-3 was commercially obtained from Cell Signaling Technologies (Beverly, MA, USA; catalog no. 9251).
Oligonucleotide microarray
The protocol used for the sample preparation and microarray processing is available from Affymetrix (Santa Clara, CA, USA). Briefly, at least 5 mg of purified RNA was reverse transcribed using Superscript II reverse transcriptase (Life Technologies, Grand Island, NY, USA) with the primer T7-dT24 containing a T7 RNA polymerase promoter. After a second strand of cDNA was synthesized with RNase H, Escherichia coli DNA polymerase and E. coli DNA ligase, the cDNA was transcribed in vitro to produce biotin-labeled cRNA with a MEGAscript High Yield Transcription Kit (Ambion, Austin, TX, USA) as recommended by the manufacturer. After the cRNA was linearly amplified with T7 polymerase, the biotinylated cRNA was cleaned with an RNeasy Mini Column Kit (Qiagen, Valencia, CA, USA), fragmented to 50-200 nucleotides, and then hybridized to the Affymetrix Human Genome U133 Plus 2.0 Array. The stained microarray was scanned with a GeneArray Scanner (Affymetrix) and the intensity of the signal was calculated with Affymetrix software, Microarray Suite 5.0. All data were scaled with the global scaling method to adjust the target intensity to 300. Then, we chose those genes with at least a 10-fold increase in the expression of the EVI1 High AML cells compared with low levels of EVI1 (EVI1 Low ) AML cells with a statistical significance of P less than 0.01 by the t-test.
Reverse-transcription polymerase chain reaction
The levels of CD52, EVI1 and b-actin mRNA in the AML cells were measured by RT-PCR. Briefly, total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA), and 1 mg of total RNA was reverse-transcribed to obtain first-strand cDNA using an RNA-PCR kit (Takara-Bio Inc., Tokyo, Japan). cDNA fragments were amplied by PCR using specic primers. The primers used were as follows: CD52 forward, 5
Establishment of stable U937 cell lines expressing EVI1
pGCDMsam-EVI1-IRES-EGFP was kindly provided by Dr A Iwama (Chiba University, Chiba, Japan). To produce recombinant retrovirus, the plasmid DNA was transfected into 293gp cells along with the vesicular stomatitis virus G expression plasmid by CaPO 4 co-precipitation. For retroviral transduction, 1 Â 10 5 U937 cells were plated in 96-well flat-bottomed plates and were infected with either an EVI1 retroviral supernatant (pGCDMsam-EVI1-IRES-EGFP) or a mock retroviral supernatant (pGCDMsam-IRES-EGFP) with 100 ng/ml polybrene for 24 h. After 7 days, green fluorescent protein-positive U937 cells were sorted with a JSAN cell sorter (Bay Bioscience, Kobe, Japan).
Establishment of stable UCSD/AML1 cell lines expressing shEVI1
A DNA-based small hairpin (sh) RNA expression vector (pSIREN-retroQ-ZsGreen plasmid; Takara-Bio, Inc.) was used in the EVI1 knockdown experiment. The following sequence was cloned into the BamHI-EcoRI site of the plasmid to create an shRNA against human EVI1: (ref . 22) 5 0 -GATCGCTCTAAGG CTGAACTAGCAGTTCAAGAGACTGCTAGTTCAGCCTTAGATT TTTTG-3 0 . A pSIREN-retroQ-ZsGreen-shLuc plasmid containing shRNA against luciferase (Takara-Bio Inc.) was used as a control. Retroviral particles were generated using the p10A1 packaging vector (Takara-Bio Inc.) and transient transfection of the 293T cell line, which was carried out with a Hilymax liposome transfection reagent (Dojindo, Kumamoto, Japan). For retroviral infection, 1 Â 10 6 UCSD/AML1 cells were placed in 6 cm dishes containing 5 ml of retroviral supernatant with 100 ng/ml polybrene for 24 h. ZsGreen-positive UCSD/AML1 cells were sorted with a JSAN cell sorter (Bay Bioscience) 2 weeks after viral infection. The repression of EVI1 expression was confirmed by RT-PCR as described above.
Flow cytometry analysis
The cells were stained with the biotinylated CAMPATH-1H on ice for 15 min. They were washed and then labeled with a phycoerythrin-labeled streptavidin antibody on ice for 15 min. After washing, the treated cells were analyzed on a FACScan (Becton Dickinson, San Jose, CA, USA).
Cell growth inhibition assay
Leukemia cells (2 Â 10 5 cells per ml) were incubated with various concentrations of CAMPATH-1H in complete medium at 37 1C in 5% CO 2 . The cell growth was evaluated with the Trypan blue exclusion assay. The live cells were enumerated after Trypan blue staining using light microscopy.
Apoptosis assay
Apoptosis assays were performed using the Apoptosis Detection kit (MBL, Nagoya, Japan) according to the manufacturer's protocol. UCSD/AML1, HNT-34 or PT8 cells (2 Â 10 5 cells per ml) were incubated with CAMPATH-1H (10 mg/ml) in complete medium at 37 1C in 5% CO 2 for 48 h. The cells were washed and resuspended in binding buffer at a concentration of 1 Â 10 6 cells per ml. The suspension was then incubated with 5 ml of Annexin-V and 5 ml of propidium iodide for 15 min at room temperature in the dark. Samples were analyzed using a FACScan (Becton Dickinson). Annexin-V-positive cells were considered apoptotic.
Cytotoxicity assays
The CDC and ADCC activities of CAMPATH-1H were measured by a lactate dehydrogenase (LDH)-releasing assay using a cytotoxicity detection kit (Roche, Indianapolis, IN, USA).
EVI1
High AML cells (1 Â 10 4 ) were incubated with various concentrations of CAMPATH-1H and human serum as the source of complement at a dilution of 1:6 (for the CDC assay) or with human PB mononuclear cells as effector cells (effector: target, 50:1 for the ADCC assay) in supplemented RPMI 1640 at 37 1C in 96-well flat-bottomed plates. After an additional incubation for 4 h at 37 1C, the extent of cell lysis was determined by measuring the amount of LDH released into the culture supernatant. The maximum LDH release was determined for cells lysed with 2% Triton X-100. The percentage of specific lysis was calculated according to the following formula: CDC % specific lysis ¼ 100 Â (EÀS)/(MÀS), where E is the absorbance of the experimental well, S is the absorbance in the absence of monoclonal antibody (cells were incubated with medium and complement alone) and M is the maximum release of target cells (activity released from target cells lysed with 2% Triton X-100); ADCC % specific lysis ¼ 100 Â (EÀS E ÀS T )/(MÀS E ), where E is the experimental release (supernatant activity from target cells incubated with antibody and effector cells), S E is the spontaneous release in the presence of effector cells with antibody (supernatant activity from target cells incubated with effector cells), S T is the spontaneous release of target cells (supernatant activity from target cells incubated with medium alone) and M is the maximum release of target cells (activity released from target cells lysed with 2% Triton X-100). CD52 is a molecular target of AML with EVI1 High expression Y Saito et al
Xenograft tumors
Six-to eight-week-old female NOG mice were given a single subcutaneous injection of 5 Â 10 6 UCSD/AML1 cells suspended in 100 ml phosphate-buffered saline (PBS) and mixed with an equal volume of Matrigel (BD Matrigel, BD Biosciences, Bedford, MA, USA). Xenografts were allowed to establish to an average size of 50-100 mm 3 , after which mice were randomized into two groups. The groups of mice were given either PBS or CAMPATH-1H at a dose of 100 mg weekly intravenously for 4 weeks. Tumor volumes were derived as the product of the length, width and height of the tumor measured once a week with a caliper. A Kaplan-Meier survival analysis was performed using StatView (SAS Institute, Cary, NC, USA).
Data analysis
A faculty statistician analyzed the data. P-values were calculated using the Student's t-test for a comparison of independent data sets. Differences were considered statistically significant if the P-value was less than 0.05.
Results
EVI1
High myeloid leukemia cells express high levels of CD52
To search for novel molecular targets in refractory myeloid leukemia with EVI1 High , we initially analyzed the gene expression profiles of 12 human myeloid cell lines using an oligonucleotide microarray (Human Genome U133 Plus 2. 0 Array; Affymetrix) containing 38 500 genes. Four cell lines with chromosome 3q26 abnormalities (UCSD/AML1, HNT-34, Kasumi-3 and MOLM-1) expressed EVI1
High , and eight myeloid cell lines without chromosome 3q26 abnormalities (HEL, HL-60, K052, THP-1, FKH-1, K051, NH and OIH-1) expressed EVI1 Low (Figure 1a ). When the expression profiles between EVI1
High and EVI1 Low leukemia cell lines were compared, we detected 26 genes that were upregulated over 10-fold in EVI1
High leukemia cells when compared with EVI1 Low leukemia cells (Po0.01) ( Table 1) . Among these genes, nine genes encode membrane proteins containing extracellular domains. These genes include the CD52 antigen (CAMPATH-1 antigen). Because a humanized anti-CD52 antibody, CAMPATH-1H, has already been developed for immunosuppression before bone marrow transplantation and for gene-targeted therapy for CD52 is a molecular target of AML with EVI1 High expression Y Saito et al lymphoproliferative disorders, we further analyzed whether the CD52 antigen is a novel target in EVI1 High AML. In the next experiment, CD52 expression was examined in 15 myeloid leukemia cell lines and primary leukemia cells from 12 patients with AML using RT-PCR. We included three additional cell lines without chromosome 3q26 abnormalities (U937, K562 and KG-1) in the analysis. The CD52 expression levels in four cell lines with EVI1
High expression (UCSD/AML1, HNT-34, Kasumi-3 and MOLM-1) were higher than that in the other 11 cell lines with EVI1
Low expression (Figure 1b, top) . In primary leukemia cells, EVI1 and CD52 were more highly expressed in nine patients with chromosome 3q26 abnormalities than that in three patients without chromosome 3q26 abnormalities (Figure 1b, bottom) . Thus, CD52 may be a potential marker for EVI1
High myeloid leukemia cells.
CAMPATH-1H identifies the CD52 antigen on the surface of EVI1 High myeloid leukemia cells
Next, we determined the surface expression of the CD52 antigen by FACS analysis using phycoerythrin-labeled CAMPATH-1H ( Figure 2a ). We used control PB lymphocytes from a healthy volunteer and two B lymphoid leukemia cell lines (BALL1 and RAMOS) as positive controls and 63.6-89.7% of these cells were labeled by CAMPATH-1H. In EVI1 Low myeloid leukemia cell lines (U937, NH and K562) and primary AML cells from a patient with EVI1 Low (PT1), 2.4-10.4% of the cells were labeled by CAMPATH-1H with a low signal intensity. In contrast, 56.4-98.7% of EVI1
High myeloid leukemic cells (UCSD/AML1, HNT-34, Kasumi-3 and MOLM1) were robustly labeled by CAMPATH-1H, yielding higher signal intensity than BALL1 and RAMOS cells. Moreover, CAMPATH-1H bound to the majority of leukemia cells from three AML patients with inv(3)(q21q26) (PT8 and PT9) or with t(3;21)(q26;q22) (PT11) at a high signal intensity similar to EVI1 High cell lines. To determine whether the EVI1 transcription factor activates CD52 gene expression, we introduced an EVI1 expression vector into an EVI1
Low leukemia cell line, U937, and an shRNA targeting EVI1 (shEVI1) into an EVI1
High leukemia cell line, UCSD/AML1. After introducing the EVI1 expression vector into U937 cells, the expression of EVI1 was clearly detected in U937/EVI1 cells by RT-PCR, and the level of CD52 mRNA was also increased in U937/EVI1 cells in comparison with parental or mock vector-transfected cells (Figure 2b ). FACS analysis showed that the population of CD52-positive cells was increased (61.1%) in U937/EVI1 cells in comparison to U937/ mock cells (19.3%), with increased fluorescence intensity (Figure 2c) . Moreover, after the introduction of shEVI1 or shRNA against luciferase (shLuc) as a control into UCSD/AML1 cells, the expression level of CD52 mRNA was decreased in UCSD/AML1/shEVI1 cells, along with a decreased expression of EVI1, when compared with parental or UCSD/AML1/shLuc cells (Figure 2d) . FACS analysis showed that the percentage of CD52-positive cells in AML1/shEVI1 cells was considerably lower (24.0%) than that in AML1/shLuc (45.1%) cells with decreased fluorescence (Figure 2e) . Thus, the CD52 expression in myeloid leukemic cells is partly dependent on the expression of EVI1, and CD52 may be one of the downstream target genes regulated directly or indirectly by EVI1.
CAMPATH-1H induced a direct cytotoxic effect on EVI1
High AML cells
Because CAMPATH-1H was highly reactive with the surface of EVI1 High AML cells, it may be a good therapeutic candidate for EVI1-positive AML. We initially tested the growth inhibitory and direct cytotoxic effects of CAMPATH-1H on an EVI1
Low AML cell line (K562) and two EVI1
High AML cell lines (UCSD/AML1 and HNT-34) with two B-ALL cell lines (BALL1 and RAMOS) as controls. After the cells were incubated with various concentrations of CAMPATH-1H for 48 h, the cell viability was evaluated by Trypan blue staining (Figure 3a) . Cell growth was inhibited in the three AML cell lines with EVI1
High expression in a dose-dependent manner, and 51.5-78.9% of cells remained viable at 10 mg/ml CAMPATH-1H. In contrast, over 90% of B-ALL cells were viable at this drug concentration. In the next experiment, primary AML cells from a patient with EVI1
Low expression (PT1) and from three patients with EVI1
High expression (PT8, PT9 and PT11) were used to test the direct cytotoxic effect of CAMPATH-1H. Over 90% of PT1 cells were viable at all drug concentrations; however, only 52.5-57.5% of EVI1 High AML cells from patients (PT8, PT9 and PT11) survived the maximal dose of 100 mg/ml, suggesting that CAMPATH-1H directly suppressed the survival of EVI1
High AML cells. To confirm whether the cytotoxic effect of CAMPATH-1H is dependent on apoptotic cell death, we treated two EVI1 High AML cells underwent apoptosis 2 days after treatment (Figures 3c, d and f) . Moreover, the amount of cleaved caspase-3 (18 kDa) was increased in the EVI1 High leukemic cells after 2 days of CAMPATH-1H treatment (Figure 3h) . Thus, our results indicate that CAMPATH-1H effectively induces apoptosis in EVI1 High AML cells.
CAMPATH-1H-mediated CDC and ADCC against EVI1
Because CAMPATH-1H exerts its antitumor effects on lymphocytes or lymphoid leukemia cells through immunological mechanisms, such as CDC and/or ADCC, by virtue of its 
High AML cell lines (UCSD/AML1 and HNT-34) along with EVI1 Low AML (K562) and B-ALL cell lines (BALL1 and RAMOS) as controls. CAMPATH-1H treatment induced a slight increase in cell death in the two B-ALL and two EVI1 High AML cell lines, although it had no effect on the EVI1 Low K562 cell line (Figure 4a, left panel) . Next, primary AML cells from a patient with EVI1 Low (PT1) and from three patients with EVI1
High expression (PT8, PT9 and PT11) were used to test the effect of CAMPATH-1H on CDC. Only a low level of cell death was observed in the PT1 and PT8 cells, but a moderate CDC effect was observed using the PT-9 and PT11 cells (Figure 4a, right panel) . Thus, CAMPATH-1H does not appear to have a significant CDC effect on EVI1 High AML cells. Next, the ADCC activity of CAMPATH-1H was examined against the same cell lines and primary AML cells as those in the CDC. In the two B-ALL and two EVI1
High leukemia cell lines, CAMPATH-1H significantly increased the percentages of cell death in a dose-dependent manner, whereas EVI1 Low K562 cells showed almost no response (Figure 4b, left panel) . Treatment 
CD52 is a molecular target of AML with EVI1
High expression Y Saito et al with CAMPATH-1H also resulted in a significant increase in cell death in primary cells from three patients with EVI1 High AML (PT8, PT9 and PT11), and no response was observed in the case of the EVI1 Low PT1 cells (Figure 4b , right panel). These results suggest that CAMPATH-1H exerts a significantly stronger ADCC effect than a CDC effect against EVI1 High AML.
In vivo antitumor effect of CAMPATH against EVI1 High AML in a xenograft model
To investigate the effects of CAMPATH-1H on EVI1 High AML in vivo, USCD/AML1 cells with EVI1
High expression were subcutaneously inoculated into immunodeficient NOG mice. After tumors reached a size of 50-100 mm 3 , 100 mg of CAMPATH-1H or PBS as a control was intravenously injected once a week for 4 weeks, and tumor growth and mouse survival were monitored (Figures 4c and d) . CAMPATH-1H significantly inhibited the tumor growth of UCSD/AML1 cells when compared with the control (Po0.05) (Figure 4c) . The median survival time of control mice was 75 days, and all control mice died within 100 days. In contrast, the median survival was prolonged to 127 days in mice injected with CAMPATH-1H, and four out of five mice were still alive more than 100 days after inoculation. Taken together, these data suggest that CAMPATH-1H is a promising candidate therapeutic antibody for AML patients with EVI1
Discussion
In this study, we found that CD52 was highly expressed in most EVI1 High leukemia cells. Using the humanized anti-CD52 monoclonal antibody CAMPATH-1H, we showed that CAM-PATH-1H inhibited cell growth and induced apoptosis of EVI1 High leukemia cells through direct cytotoxicity and/or ADCC in vitro. Moreover, we showed the therapeutic efficacy of CAMPATH-1H in an in vivo model of EVI1
High leukemia using NOG mice. Although NOG mice lack functional T and natural killer cells, murine neutrophils were considered to be effector cells mediating ADCC as well as direct cytotoxicity in our mouse model. Indeed, CAMPATH-1H efficiently inhibited the growth of leukemia xenografts in an EVI1 High AML xenograft model. These data suggest that the use of CAMPATH-1H may be effective in treating myeloid leukemia with EVI1
High . CD52 is a small glycosylphosphatidylinositol-linked protein of unknown function. CAMPATH-1H (Alemtuzumab), a humanized antibody against CD52, is used to deplete leukemia cells from patients with relapsed/refractory chronic lymphocytic leukemia. 15 Recent studies have suggested the effectiveness of CAMPATH-1H treatment in additional hematopoietic malignancies, including peripheral T-cell lymphoma, T-cell prolymphocytic leukemia and cutaneous T-cell lymphoma. [40] [41] [42] Although it has been reported that the majority of various subtypes of AML are negative for CD52 expression, a subset of acute myelomonocytic leukemias has been shown to exhibit CD52 expression. 13 This is consistent with our observation that a case (no. 2) out of 10 EVI1
Low AML cases has been diagnosed with myelomonocytic leukemia with high CD52 expression (Supplementary Figure S1) . Recently, it was reported that 15 patients with CD52-positive, recurrent or refractory acute leukemia (nine patients with AML and six patients with ALL) received single-agent Alemtuzumab.
14 Interestingly, the majority of the CD52-positive AML cases had chromosome 7 abnormalities, and two cases with monosomy 7 exhibited complete remission. In our study, five of nine AML patients with
EVI1
High expression displayed chromosomal abnormalities involving chromosome 7, such as t(3;7)(q26;q21), partial deletion of chromosome 7 or monosomy 7. Patients with EVI1
High AML exhibit specific clinical features, including elevated platelet counts, association with monosomy 7 or chromosome 7 deletion, refractoriness to therapy and a poor prognosis. 43 It has been suggested that the genomic instability and myelodysplasia with monosomy 7 occur as a consequence of EVI1 activation after gene therapy for chronic granulomatous disease. 44 It seems likely that EVI1 and gene(s) on chromosome 7 play a crucial role in regulating CD52 expression. We have previously shown that EVI1 is expressed on bone marrow stem and progenitor cells and has an important function in maintaining hematopoietic stem cells. 45 It is, therefore, tempting to speculate that specific stem cell populations may express CD52 along with EVI1. Future studies should examine the expression of CD52 on hematopoietic stem cells and its relevance to leukemia development. It is also important to determine whether EVI1 directly activates the CD52 promoter.
Although the mechanism of cytotoxicity of CAMPATH-1H is not well understood, CAMPATH-1H had minimal direct cytotoxicity, but exhibited significant CDC against chronic lymphocytic leukemia and acute lymphocytic leukemia cells. 18, 19 In our experiments, CAMPATH-1H lysed EVI1
High AML cells more efficiently through direct cytotoxicity or ADCC than through CDC (Figures 3 and 4) . CD52 is a 12-amino-acid glycopolypeptide containing a large glucose moiety, and CAMPATH-1H recognizes C-terminal amino acids and part of the glycosylphosphatidylinositol anchor of CD52. 46, 47 The amount of protein and/or post-translational modifications, such as glycosylation, may be involved in differential immune responses to CAMPATH-1H.
We showed that EVI1 High AML cells are good targets for the cytolytic activity of CAMPATH-1H. In the standard schedule of CAMPATH-1H for allogeneic stem cell transplantation, the treatment is not always efficient because the antibody adsorbs onto T lymphocytes. Therefore, combinations of CAMPATH-1H with active chemotherapeutic agents such as daunorubicin, etoposide and cytarabine need to be explored in future studies. Finally, these studies provide support for a clinical trial of CAMPATH-1H in patients with EVI1 High AML and potentially in patients with other AMLs that express CD52.
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